Adalimumab fosimdesonide clinical trials
Also written ABBV-154.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses adalimumab fosimdesonide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ABBV-154
- 3
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses adalimumab fosimdesonide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154TerminatedPhase 2AbbVieNCT04972968Written as ABBV-154
- Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)TerminatedPhase 2AbbVieNCT04888585Written as ABBV-154
- A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's DiseaseTerminatedPhase 2AbbVieNCT05068284Written as ABBV-154
- Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy ParticipantsCompletedPhase 1AbbVieNCT05556226Written as ABBV-154 Dose Formulation A
Codes
What other systems call adalimumab fosimdesonide · ClinicalTrials.gg INT016603
- UNII (FDA) FWC6IWT3EHADALIMUMAB FOSIMDESONIDEOne source FDA
- NCI Thesaurus C190447Adalimumab FosimdesonideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FWC6IWT3EH | ADALIMUMAB FOSIMDESONIDE | One source FDA |
| NCI Thesaurus | C190447 | Adalimumab Fosimdesonide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.